How effective is ruxolitinib cream in treating psoriasis? How to evaluate the efficacy and improvement after use?

Ruxolitinib cream (Opzelura) is a topical immunomodulatory drug used primarily to treat psoriasis (especially mild to moderate localized psoriasis). As a Januskinase inhibitor, it reduces the immune system's overreaction by inhibiting the JAK signaling pathway, thereby reducing the symptoms of psoriasis, such as redness, scale and inflammation of the skin. Research shows that ruxolitinib cream has significant efficacy in clinical treatment and can effectively improve patients' symptoms.

Ruxolitinib cream through topical application inhibits Januskinases (JAK) 1 and JAK3 , regulating signaling in the immune system. Psoriasis is a skin disease caused by an abnormality in the immune system. An overactive immune system causes skin cells to proliferate too quickly, forming the typical psoriatic plaques. By inhibiting the JAK pathway, ruxolitinib cream effectively slows down the abnormal proliferation of skin cells and immune response, thereby reducing skin redness and scales and helping patients return to normal skin condition.

Clinical studies have shown that ruxolitinib cream has good efficacy in the treatment of psoriasis. Most patients experience significant relief from skin redness, swelling, scaling, and itching after using the drug. After several weeks of treatment, patients' skin conditions improved significantly, and many experienced partial or complete relief of symptoms. Clinical observation also found that ruxolitinib cream is more effective when applied topically, especially in patients with mild to moderate psoriasis.

Effectiveness is usually assessed based on the Psoriasis Area and Severity Index (PASI) and patient self-reported improvement in symptoms. In multiple clinical trials, ruxolitinib creamhas been shown to be effective in reducingPASI scores, especially in the first few weeks of treatment. The size of skin patches after treatment was significantly reduced, and the inflammatory response was controlled. Patients reported that skin pain and itching were reduced, and their overall quality of life was improved. In addition, ruxolitinib cream has milder side effects when used locally than systemic drugs, so it is also a safer treatment option.

Reference materials:https://www.opzelura.com/